Libtayo fda approval history last updated by judith stewart, bpharm on oct 9, 2025 Last week, regeneron announced the u.s Yes (first approved september 28, 2018) brand name
Patel, md, discusses the fda approval of cemiplimab in cutaneous squamous cell carcinoma This new approval is intended for patients who have. Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation.
Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo This approval brings hope to adults with cscc who are at high risk of the cancer coming back, offering another way to lower the chances of recurrence